DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease

Pediatric Rheumatology

Volumn 11, Issue 1, 2013, Pages

  Portman, Michael A ^a   Wiener, Howard W ^b   Silva, Miriam ^a   Shendre, Aditi ^b   Shrestha, Sadeep ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Coronary artery disease; DC SIGN; Fc R; IVIG treatment response; Kawasaki disease

Indexed keywords

CD209 ANTIGEN; IMMUNOGLOBULIN;

ARTICLE; ASIAN; CONTROL; CONTROLLED STUDY; ETHNIC GROUP; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 84884353491     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-11-32     Document Type: Article

References (27)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967, 16(3):178-222.
2. Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol Online J 2011, 9:17. 10.1186/1546-0096-9-17, 3163180, 21774801.
3. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984, 2(8411):1055-1058.
4. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, Mason WH, Meissner HD, Rowley AH, Shulman ST, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen FS. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324(23):1633-1639. 10.1056/NEJM199106063242305, 1709446.
5. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986, 315(6):341-347. 10.1056/NEJM198608073150601, 2426590.
6. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young. American Heart Association. Pediatrics 2004, 114(6):1708-1733. 10.1542/peds.2004-2182, 15574639.
7. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, Balfour I, Shen CA, Michel ED, Shulman ST, Melish ME. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005, 146(5):662-667. 10.1016/j.jpeds.2004.12.022, 15870671.
8. Portman MA, Olson A, Soriano B, Dahdah N, Williams R, Kirkpatrick E. Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. Am Heart J 2011, 161(3):494-499. 10.1016/j.ahj.2010.12.003, 21392603.
9. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313(5787):670-673. 10.1126/science.1129594, 16888140.
10. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291(5503):484-486. 10.1126/science.291.5503.484, 11161202.
11. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008, 105(50):19571-19578. 10.1073/pnas.0810163105, 2604916, 19036920.
12. Despres P, Sakuntabhai A, Julier C. A variant in the CD209 (DC-SIGN) promoter is associated with severity of dengue disease. Med Sci (Paris) 2005, 21(11):905-906.
13. Gomez LM, Anaya JM, Sierra-Filardi E, Cadena J, Corbi A, Martin J. Analysis of DC-SIGN (CD209) functional variants in patients with tuberculosis. Hum Immunol 2006, 67(10):808-811. 10.1016/j.humimm.2006.07.003, 17055357.
14. Martin MP, Lederman MM, Hutcheson HB, Goedert JJ, Nelson GW, Van-Kooyk Y, Detels R, Buchbinder S, Hoots K, Vlahov D, O'Brien SJ, Carrington M. Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. J Virol 2004, 78(24):14053-14056. 10.1128/JVI.78.24.14053-14056.2004, 533922, 15564514.
15. Shrestha S, Wiener H, Shendre A, Kaslow RA, Wu J, Olson A, Bowles NE, Patel H, Edberg JC, Portman MA. Role of activating FcgammaR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response. Circ Cardiovasc Genet 2012, 5(3):309-316. 10.1161/CIRCGENETICS.111.962464, 3444514, 22565545.
16. Shrestha S, Wiener HW, Olson AK, Edberg JC, Bowles NE, Patel H, Portman MA. Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease. J Allergy Clin Immunol 2011, 128(3):677-680. 10.1016/j.jaci.2011.04.027, 3444515, 21601260.
17. Sakuntabhai A, Turbpaiboon C, Casademont I, Chuansumrit A, Lowhnoo T, Kajaste-Rudnitski A, Kalayanarooj SM, Tangnararatchakit K, Tangthawornchaikul N, Vasanawathana S, Chaiyaratana W, Yenchitsomanus PT, Suriyaphol P, Avirutnan P, Chokephaibulkit K, Matsuda F, Yoksan S, Jacob Y, Lathrop GM, Malasit P, Despres P, Julier C. A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet 2005, 37(5):507-513. 10.1038/ng1550, 15838506.
18. Barreiro LB, Neyrolles O, Babb CL, Tailleux L, Quach H, McElreavey K, Helden PD, Hoal EG, Gicquel B, Quintana-Murci L. Promoter variation in the DC-SIGN-encoding gene CD209 is associated with tuberculosis. PLoS Med 2006, 3(2):e20. 10.1371/journal.pmed.0030020, 1324949, 16379498.
19. Boily-Larouche G, Milev MP, Zijenah LS, Labbe AC, Zannou DM, Humphrey JH, Ward BJ, Poudrier J, Mouland AJ, Cohen EA, Roger M. Naturally-occurring genetic variants in human DC-SIGN increase HIV-1 capture, cell-transfer and risk of mother-to-child transmission. PLoS One 2012, 7(7):e40706. 10.1371/journal.pone.0040706, 3393705, 22808239.
20. Chan KY, Xu MS, Ching JC, So TM, Lai ST, Chu CM, Yam LY, Wong AT, Chung PH, Chan VS, Lin CL, Sham PC, Leung GM, Peiris JS, Khoo US. CD209 (DC-SIGN) -336A > G promoter polymorphism and severe acute respiratory syndrome in Hong Kong Chinese. Hum Immunol 2010, 71(7):702-707. 10.1016/j.humimm.2010.03.006, 20359516.
21. Chaudhary O, Rajsekar K, Ahmed I, Verma R, Bala M, Bhasin R, Luthra K. Polymorphic variants in DC-SIGN, DC-SIGNR and SDF-1 in high risk seronegative and HIV-1 patients in Northern Asian Indians. J Clin Virol 2008, 43(2):196-201. 10.1016/j.jcv.2008.06.005, 18775666.
22. Wang L, Chen RF, Liu JW, Lee IK, Lee CP, Kuo HC, Huang SK, Yang KD. DC-SIGN (CD209) Promoter -336 A/G polymorphism is associated with dengue hemorrhagic fever and correlated to DC-SIGN expression and immune augmentation. PLoS Negl Trop Dis 2011, 5(1):e934. 10.1371/journal.pntd.0000934, 3014977, 21245921.
23. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young. American Heart Association. Circulation 2004, 110(17):2747-2771. 10.1161/01.CIR.0000145143.19711.78, 15505111.
24. Yu HR, Chang WP, Wang L, Lin YJ, Liang CD, Yang KD, Kuo CM, Huang YC, Chang WC, Kuo HC. DC-SIGN (CD209) promoter -336 A/G (rs4804803) polymorphism associated with susceptibility of Kawasaki disease. Sci World J 2012, 2012:634835.
25. Holman RC, Belay ED, Christensen KY, Folkema AM, Steiner CA, Schonberger LB. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J 2010, 29(6):483-488.
26. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP,US/Canadian Kawasaki Syndrome Study Group Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998, 17(12):1144-1148. 10.1097/00006454-199812000-00009, 9877364, US/Canadian Kawasaki Syndrome Study Group.
27. Makowsky R, Wiener HW, Ptacek TS, Silva M, Shendre A, Edberg JC, Portman MA, Shrestha S. FcgammaR gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response. Pharmacogenet Genomics 2013, 23(9):455-462. 10.1097/FPC.0b013e328363686e, 23778324.